Heeren TFC - Search Results

1

Dark-Adapted Two-Color Fundus-Controlled Perimetry in Macular Telangiectasia Type 2.

Heeren TFC, Tzaridis S, Bonelli R, Pfau M, Fruttiger M, Okada M, Egan C, Charbel Issa P, Holz FG. Heeren TFC, et al. Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1760-1767. doi: 10.1167/iovs.18-25360. Invest Ophthalmol Vis Sci. 2019. PMID: 31022297

2

Macular telangiectasia type 2.

Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HP. Charbel Issa P, et al. Prog Retin Eye Res. 2013 May;34:49-77. doi: 10.1016/j.preteyeres.2012.11.002. Epub 2012 Dec 3. Prog Retin Eye Res. 2013. PMID: 23219692 Free PMC article. Review.

3

[Bullous keratopathy].

Heeren T, Holz FG, Löffler KU. Heeren T, et al. Ophthalmologe. 2013 Nov;110(11):1069-72. doi: 10.1007/s00347-013-2893-z. Ophthalmologe. 2013. PMID: 23793733 German. No abstract available.

4

First symptoms and their age of onset in macular telangiectasia type 2.

Heeren TF, Holz FG, Charbel Issa P. Heeren TF, et al. Retina. 2014 May;34(5):916-9. doi: 10.1097/IAE.0000000000000082. Retina. 2014. PMID: 24351446

5

[Morphological characteristics in macular telangiectasia type 2].

Charbel Issa P, Heeren TF, Krüger E, Zeimer M, Pauleikhoff D, Holz FG. Charbel Issa P, et al. Ophthalmologe. 2014 Sep;111(9):819-28. doi: 10.1007/s00347-014-3082-4. Ophthalmologe. 2014. PMID: 25204527 German.

6

[Functional characteristics of macular telangiectasia type 2].

Heeren TF, Krüger E, Holz FG, Charbel Issa P. Heeren TF, et al. Ophthalmologe. 2014 Sep;111(9):829-33. doi: 10.1007/s00347-014-3083-3. Ophthalmologe. 2014. PMID: 25204528 German.

7

[Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].

Holz FG, Heeren TF, Krüger E, Zeimer M, Pauleikhoff D, Charbel Issa P. Holz FG, et al. Ophthalmologe. 2014 Sep;111(9):834-8. doi: 10.1007/s00347-014-3084-2. Ophthalmologe. 2014. PMID: 25204529 German.

8

In-vivo mapping of drusen by fundus autofluorescence and spectral-domain optical coherence tomography imaging.

Göbel AP, Fleckenstein M, Heeren TF, Holz FG, Schmitz-Valckenberg S. Göbel AP, et al. Graefes Arch Clin Exp Ophthalmol. 2016 Jan;254(1):59-67. doi: 10.1007/s00417-015-3012-4. Epub 2015 Apr 24. Graefes Arch Clin Exp Ophthalmol. 2016. PMID: 25904296

9

Progression of Vision Loss in Macular Telangiectasia Type 2.

Heeren TF, Clemons T, Scholl HP, Bird AC, Holz FG, Charbel Issa P. Heeren TF, et al. Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3905-12. doi: 10.1167/iovs.15-16915. Invest Ophthalmol Vis Sci. 2015. PMID: 26070062

10

POOR LONG-TERM OUTCOME OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2.

Kupitz EH, Heeren TF, Holz FG, Charbel Issa P. Kupitz EH, et al. Retina. 2015 Dec;35(12):2619-26. doi: 10.1097/IAE.0000000000000715. Retina. 2015. PMID: 26340529

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters